NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Pilatus Biosciences

Pilatus Biosciences

Private
LausanneHealthcare & Life Scienceshttps://www.pilatusbio.com/

Last Round

Pre Seed

Dec 15, 2025

Total Funding Raised

$14M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Pilatus Biosciences is a biotechnology company that develops first-in-class antibodies and bifunctional proteins targeting metabolic checkpoints to reprogram the tumor microenvironment for cancer immunotherapy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

metabolic checkpointimmunotherapyoncology drugcancer immunotherapybiopharmaceuticalclinical-stage biotechdrug developmentliver cancer treatmentgastrointestinal cancerbiotech startupclinical trialdrug discoverytherapeutic assetsbiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pilatus Biosciences Comparables

Compare Pilatus Biosciences with similar companies based on industry and business-model similarity.

Pilatus Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Elixiron Immunotherapeutics
69%
Vigeo Therapeutics
66%
Bristol Myers Squibb
66%

Pilatus Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedDec 15, 2025

Pilatus Biosciences Investors

Notable investors and investment history

Pilatus Biosciences investors
InvestorRounds
Tiger Jade Pebble AcceleratorPre Seed
Cancer Research InstitutePre Seed
Mosaic Venture LabPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 10, 2026

    Grew 30% QoQ, from 10 to 13 employees.

  • Apr 23, 2026

    Monthly visitors increased 37% to 2.6K.

Pilatus Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pilatus Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pilatus Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersLausanne
Employee Range13
Year Founded2022
Last FundingDec 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.